Pasithea Therapeutics approves new executive/director compensation and option grants at $0.715

Pasithea Therapeutics Corp.

CEO Tiago Reis Marques base salary increased to $533,000; target bonus reduced to 55%.
CFO Daniel Schneiderman base salary increased to $391,000; target bonus at 40%.
Stock options granted: CEO 493,341 shares, CFO 317,266, employees 352,266 total.
Board Chair annual cash compensation reduced from $100K to $35K; consulting fees cut to $1/quarter.
Non-employee directors each receive 42,913 share options; Prof. Steinman gets one-time 200,000 share option.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.